High-cost generic drugs - Implications for patients and policymakers

New England Journal of Medicine

Volumn 371, Issue 20, 2014, Pages 1859-1862

  Alpern, Jonathan D ^a,b   Stauffer, William M ^a,b   Kesselheim, Aaron S ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; CAPTOPRIL; CLOMIPRAMINE; DIGOXIN; DOXYCYCLINE HYCLATE; GENERIC DRUG; MEBENDAZOLE; PYRIMETHAMINE; ANTIPARASITIC AGENT;

DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG RECALL; DRUG SAFETY; ECHINOCOCCOSIS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART FAILURE; HUMAN; HYPERTENSION; MEDICAID; NEUROCYSTICERCOSIS; OBSESSIVE COMPULSIVE DISORDER; PRESCRIPTION; PUBLIC HEALTH SERVICE; REVIEW; TOXOPLASMOSIS; ECONOMICS; GOVERNMENT; LAW; LEGISLATION AND JURISPRUDENCE; TRENDS; UNITED STATES;

ALBENDAZOLE; ANTIPARASITIC AGENTS; ANTITRUST LAWS; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; HUMANS; MEDICAID; UNITED STATES; UNITED STATES FEDERAL TRADE COMMISSION; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84910122550     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1408376     Document Type: Article

References (5)

1. Micromedex 2.0 (electronic version). Greenwood Village, CO: Truven Health Analytics (http://www.micromedexsolutions.com).
2. Colliver V. Prices soar for some generic drugs. SFGate. January 1, 2014 (http://www.sfgate.com/health/article/Prices-soar-for-some-generic-drugs-5105538. php).
3. Government Accountability Office. Brand-name prescription drug pricing: lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases. December 2009 (http://www.gao.gov/new.items/d10201.pdf).
4. CorePharma and GlaxoSmithKline conclude agreement on US rights for Dexedrine, Albenza and Daraprim. Press release of GlaxoSmithKline, October 22, 2010 (http://us.gsk.com/en-us/media/press-releases/2010/corepharma-and-glaxosmithkline-conclude-agreement-on-us-rights-for-dexedrineandreg-albenzaandreg-and-daraprimandreg).
5. Choudhry NK, Lee JL, Agnew-Blais J, Corcoran C, Shrank WH. Drug company-sponsored patient assistance programs: a viable safety net? Health Aff (Millwood) 2009;28:827-34.